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ABSTRACT 
Serological and molecular analyses of a cohort of HIV-1-infected intravenous drug ah users (IVDAs) (n = 
103) in Dublin, Ireland have demonstrated that 15 of 103 (14.6%) were infected with HTLV-II, which is the 
highest infection rate yet recorded for any European country. Restriction fragment length polymorphism 
(RFLP) analysis of the env region of the pro virus demonstrated that the infection involved only the HTLV-
IIa subtype; the HTLV-IIb subtype was not detected. Phylogenetic analysis of the nucleotide sequences of the 
long terminal repeat (LTR) confirmed infection with the HTLV-IIa subtype, and demonstrated that the 
viruses clustered closely with HTLV-IIa isolates from North American IVDAs. Previous observations that 
IVDAs in southern Europe, specifically Spain and Italy, appear to be infected predominantly with the HTLV-
IIb subtype, along with the present report and evidence that IVDAs in Sweden arc infected with the HTLV-
IIa subtype, suggest different origins of HTLV-II infection in Europe. 
 
INTRODUCTION 
HUMAN T LVMPHOTROPIC VIRUSES TYPE I 
(HTLV-I) and type II (HTLV-II) arc closely 
related retroviruses that have a tropism for T 
lymphocytes.1,2 HTLV-I infection is endemic in 
southwestern Japan, the Caribbean basin, and in 
parts of South America and Africa.3-8 In endemic 
areas infection has been associated with an 
aggressive CD4+ T cell malignancy, adult T cell 
leukemia (ATL)9,10; a chronic neurological 
disorder, HTLV-I-associated myelopathy/tropical 
spastic paraparesis (HAM/TSP)11,12; and a 
characteristic uveitis, HTLV-I uveitis (HUV).13,14 
HTLV-II infection has been shown lo be endemic 
in a number of native American populations15-17 
and high rates of infection have been documented 
in intravenous drug abusers (IVDAs) in North 
America, pans of western Europe, and in Southeast 
Asia.18-21 In contrast to HTLV-I, there are no 
definite associations between HTLV-II 
infection and clinical disorders; however, there is 
growing evidence that infection may be associated 
with a variety of neurological disorders, some of 
which closely resemble HAM/TSP.20-27
 Molecular characterization of HTLV-II 
isolates from North America and Europe has, 
demonstrated the existence of at least two major 
molecular subtypes, designated HTLV-IIa and 
HTLV-IIb.20 Studies of IVDAs in North America 
have suggested that HTLV-IIa is the predominant 
infection in this population.20 While studies of 
infection in European IVDAs have been somewhat 
limited, it has been suggested that in southern-
Europe (specifically Spain and Italy) this involves 
predominanlly, and in many instances exclusively, 
the HTLV-IIb subtype.18,28-38 In contrast, a single 
report from Sweden has suggested that HTLV-IIa 
predominates in that country.39.To appreciate better 
the extent of HTLV-II infections within Europe, 
we have now investigated HTLV-I1 infections in a 
cohort of HIV-l-infected IVDAs in the Republic of 
Ireland. The study 
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has demonstrated that this population has the highest rate 
of HTLV-II infection so far documented in Europe, und is 
equivalent to that seen in urban areas of the United 
Stales.20 Moreover, molecular analysis has indicated that 
this involves exclusively the HTLV-IIa subtype, suggesting 
that infections in northern and southern Europe almost 
certainly have different origins and have probably been 
introduced al different limes. 
MATERIALS AND METHODS 
Study population and serological studies 
 Venous blood samples were obtained from 103 
intravenous drug abusers (IVDAs) attending a sexually 
transmitted disease (STD) clinic and/or a drug 
rehabilitation unit in central Dublin. The subjects included 
71 males (median age. 34.25 years) and 32 females 
(median age. 32.85 years). All of the subjects were of Irish 
descent and all were seropositive for H1V-1. Sera were 
assayed using a commercially available enzyme-linked 
immunosorbent assay (ELISA) (HTLV I/1I antibody 
detection assay; Murex. Kent, U.K.) and repeatedly 
reactive samples were confirmed by Western blot (HTLV 
blot 2.4; Genelabs Diagnostics, Singapore). 
Polymerase chain reaction and restriction fragment length 
polymorphism analysis 
DNA for polymerase chain reaction (PCR) studies was 
extracted from the peripheral blood mononuclear cells 
(PBMCs), using the Puregene DNA isolation kit (Centra 
Systems, Minneapolis, MN). 
 pX region. To differentiate HTLV-I and HTLV-II 
infections, restriction fragment length polymorphism 
(RFLP) analysis of an amplified product of a region of pX 
was performed using methods previously reported.40 
Reactions were carried out in a Perkin-Elmer Cetus 
(Emeryville. CA) 9600 DNA thermal cycler and amplified 
products were digested with TaqI restriction endonuclease 
(Stratagene, La Jolla, CA) in accordance with the 
manufacturer guidelines, and analyzed by agarose gel elec-
trophoresis. 
 Envelope region. To differentiate HTLV-IIa and 
HTLV-IIb, RFLP analysis of the env region was carried 
out, Specifically, nested PCR was used to amplify a region 
encoding the envelope gp21 transmembrane protein. 
Primers employed in the first round were E2 (5’ 
CTGCAGAAGCTAGCAGGTCTA 3’) and E5 (5’ 
AGCCAAGTGTCCCTTCGACTA 3’), corresponding to 
nucleuses 6661-6641 and 5603-5623 of the HTLV-II 
isolate Mo-T. The nested primers were E2 and El (5’ 
CTGCAA-CAACTCCATTATCCT 3’J. corresponding to 
nucleotides 6031-6051 of HTLV-II Mo-T. Amplification 
was performed in 100.0-jul reaction mixtures containing 2 
µg of DNA, a 200 µM concentration of each dNTP, 40 
pmol of each primer, 10 mM Tris-HCi (pH 8.3), 50 mM 
KC1, 0.1 mM MgCl2. and 2.5 U of Taq polymerase. Five 
microliters of the amplified product from the first round of 
PCR was used as a template in the nested PCR. The same 
cycling conditions were used in both the initial and nested 
PCRs and consisted of an initial denaturation al 94°C for 5 
min, followed by 35 cycles at 94°C for 40 sec, 53°C for 30 
sec, and 72°C for 40 sec. with a final additional 10-min 
extension at 72°C The amplified product was then analysed 
following digestion with XhoI restriction endonuclease 
(Strat-ngence) as described previously.41
 Long terminal repeal region. For nucleotide 
sequencing and phylogenetic studies a 623-nucleolide 
region of the long terminal repeat (LTR) region was 
amplified from five randomly chosen pX and env PCR-
positive samples, using nested PCR. First-round PCK 
primers were F II LTRNru (5’ 
TCGCGATGACAATGGCGAC-TAGCCTC 3’), 
corresponding to nucleotides 1-20 of the HTLV-II Mo-T 
isolate plus a 6-base Nru restriction site at the 5’ end, and 
Long Gag (5’ GGGGGCTTTGGGTATTGGAGTTGGG 
3’), corresponding to nucleotides 854-83 1 of HTLV-II 
Mo-T. Nested PCR primers were MoI6 (5’ 
GCCTCCCAAGCCAGCCAC 3’P and MSW-Gag (5’ 
GGGAAAGCCCGTGGATTTGCCCCAT 3’), 
corresponding to nucleotides 16-31 and 831-807. 
respectively, of HTLV-II Mo-T. Amplifications were 
performed in 100.0-µ1 reaction mixtures containing 2 µg of 
DNA, a 200 µM concentration of each dNTP, 40 pmol of 
each primer, 10 mM Tris-HCl (pH 8.3), 50 mM KC1, 0.1 
mM MgCl2 and 2.5 U of Taq polymerase. Ten microliters 
of the first-round PCR product was used as a template for 
the nested PCR. Thermal cycling conditions used for both 
the first-round and nested PCRs included an initial 
denaturation at 94°C for 10 min, and subsequently 35 
cycles al 94°C for 40 sec, 57.6°C for 30 sec, and 72°C for 
40 sec, both of which were followed by a 10-min extension 
at 72°C. All PCR products and restriction digests were 
analyzed on 2% agarose gels followed by ethidium 
bromide staining. 
Cloning, nucleotide sequencing, and phylogenetic analysis 
 PCR products amplified from the LTR region were 
excised from agarose gels, purified using the Promega 
(Madison, WI) Wizard PCR prep system, ligated to 
plasmid PCR 2.1 (Original TA cloning kit; Invitrogcn. San 
Diego, CA) and used to transform competent Escherichia 
coli (INVaF’) under conditions recommended by the 
manufacturers. Purified plasmid DNAs from recombinant 
clones were analyzed using Taq FS dye terminator cycle 
sequencing on an ABI Prism 373 DNA stretch sequencer 
(Perkin-Elmer Cetus). Three primers — two universal, 
M13R (5’ GGAAACAGCTATGACCATG 3’) and P7 (5’ 
CGCCAGGGTTTTCCCAGTCACGAC 3’), and MSW-
LTR (5’ TGACGATTACCCCCCTGCCCATAAA 3’), 
corresponding to nucleotides 231-254 of HTLV-II Mo-T 
— were employed. Raw sequence data were aligned and 
edited using DNAsis-Mac version 2.0 (Hitachi Software 
Engineering, San Bruno, CA). Sequence alignment for 
phylogenetic analysis was performed using Geneworks 
software (IntelliGenetics, San Jose, CA). Editing of the 
alignments was done using MacClade .05 (Sinauer 
Associates, Sunderlaind, MA) and MacClade was also 
employed in the determination of the empirical average 
transition/transversion ratio of the aligned sequences. 
Phyloge-netic trees were constructed and evaluated using 
programs from PHYLIP version 3.572 (Felsenstein, 1995). 
Three independent methods were used to construct the 
trees: neighbor joining (NJ), Fitch and Wagner parsimony 
(pars), and maximum likelihood (ML). Fifty-seven HTLV-
II LTR sequences were included in the phylogenetic 
analysis, and in all of the methods an LTR sequence from a 
primate T cell lymphotropic virus (PTLV) isolated from 
Pan paniscus was used as an oulgroup.42 The empirically 
determined transition/transversion ratio was used for NJ 
and ML methods. The NJ and pars trees were evaluated 
using 1000 bootstrap replicates. 
Nucleotide sequences used in the phylogenetic analyses 
Fifty-seven HTLV-IIa and HTLV-IIb LTR sequences were 
used in the construction of the phylogenetic trees. Isolates 
and corresponding GenBank accession numbers were as 
follows. The HTLV-IIa sequences included eight european 
IVDAs (NORN2N, accession number U10258: DUB095, 
AF0329S9; DUB500. AF032990; DUB408, AF032991; 
DUB496, Af032992; DUB991, AF032993: SMH 1. 
Y09147; SMH 2. Y09148), four American IVDAs (ATLI8, 
U10252; LAS, U10256; SFIDU ao 5-5, U73010; SFIDU 
a2 6-2, U73022), four Brazilian Indians (SPWV; Braz.A21, 
U10253; KAY73, L42509: KAY139. L42508J, two North 
American Indians (PUEB.RB, U10262; NAV.DS, 
U10257), a Mexican prostitute (Mcxyl7, L42510), and the 
prototype HTLV-IIa isolate from the United Stales (Mo, 
M1060). HTLV-IIb sequences were from 22 European 
IVDAs (Gu, X89270; ITA47A, UI0254; ITA50A, U10255: 
SPAN 129, U10256; SPAN 130, UI0266: I-AM, Y09I49; 
I-EC Y09150; I-IT, Y09151; I-EA, Y09152; I-GI, Y09153; 
I-OG, Y09I54; I-OV, Y09149; RC, L77241; 130, L77242; 
324, L77243; RVP, L77244), 5 American IVDAs (JG, 
L06857; NY185, U10259; PENN7A, U10260; SFIDU bx 
4-10, U73016; SFIDU bx 6-4, U73018), 3 Colombian 
Indians (G12, LI 1456: WYUI, U12792; WYU2, U12794), 
and a Cameroon pygmy (PYGCAM1, Z46888). The 
prototype HTLV-IIb sequence NRA (120734) was also 
included. An LTR sequence from a primate T cell 
lymphotropic virus (PTLV) isolated from a pygmy 
chimpanzee, Pan paniscus, was used as an outgroup in all 
three tree-construction methods (PP1664, Z46344).42 Also 
included was an LTR sequence form an Efe pygmy from 
the Democratic Republic of Congo/Zaire (Efe2, Y14365), 
which has been designated as a new subtype, HTLV-IId.43 
RESULTS 
Serological, PCR, and KI-’LP analysis 
 All 103 sera were initially analyzed using an 
enzyme-linked immunosorbent assay (ELISA) and 
repeatedly reactive samples were confirmed by Western 
blotting (WB). Sixteen samples (15.5%) (4 female, 12 
male) were reactive on ELISA. WB confirmed that 12 of 
these (11.7%) were seropositive with the 4 remaining 
ELISA-positive samples displaying indeterminate patterns 
(4 of 103, 3.88%) (Table 1). Eleven of the 12 con-finned 
samples had WB patterns consistent with HTLV-II 
infection (10.7%), The remaining sample had a pattern 
consistent with dual HTLV-I and HTLV-II infection, in 
that there was reactivity to both HTLV-I and -II 
recombinant gp46 proteins. The Western blot reactivities 
of me four individuals with indeterminate patterns arc 
outlined in Table 2, where it can be seen that there was no 
consistent pattern of reactivity in this group. 
 DNA was extracted from PBMCs of seven HTLV-
II-seropositive individuals and the four with indeterminate 
patterns, and PCR with RFLP analysis of the tax region 
was used to confirm and differentiate HTLV-I and HTLV-
II infection.40 Amplification produced a product of the 
expected size (159 bp) and RFLP analysis based on TaqI 
restriction endonuclease digestion produced three 
fragments of 85, 53, and 21 nucleotides, confirming that all 
of the II samples including the indetermi-nates involved 
HTLV-II infection.40
 RFLP analysis of the envelope region encoding the 
trans-membrane protein gp21 was used to differentiate the 
HTLV-IIa and HTLV-IIb subtypes. Amplification of all 11 
samples resulted in the expected 63 1-nucleotide product. 
XhoI digestion resulted in two DNA fragments of 178 and 
453 nucleotides, indicating that all samples, also including 
the WB indeterminate samples, were infected with the 
HTLV-IIa subtype. The HTLV-IIb subtype was not 
detected. Unfortunately, whole blood samples could not be 
obtained from the individual who appeared to be 
seropositive for 




(years) ELISA Western blot pX env 
DUB095 M 38 Pos HTLV-II HTLV-II HTLV-IIa 
DUB 991 M 33 Pos Ind HTLV-II HTLV-IIa 
DUB408 M 36 Pos HTLV-II HTLV-II HTLV-IIa 
DUB496 M 28 Pos HTLV-II HTLV-II HTLV-IIa 
DUB500 F 34 Pos HTLV-II HTLV-II HTLV-IIa 
DUB501 M 35 Pos HTLV-U HTLV-II HTLV-IIa 
DUB611 M 33 Pos Ind HTLV-II HTLV-IIa 
DUB616 M 36 Pos HTLV-II HTLV-JI HTLV-IIa 
DUB717 M 42 Pos Ind HTLV-JI HTLV-IIa 
DUB 805 M 38 Pos HTLV-II HTLV-II HTLV-IIa 
DUB812 F 31 Pos HTLV-II HTLV-II HTLV-IIa 
DLIB215 F 41 Pos HTLV-II — — 
DUB376 M 36 Pos HTLV-II — — 
DUB472 M 42 Pos HTLV-II — — 
DUB497 M 32 Pos HTLV-I/II — — 
DUB3173 F 42 Pos HTLV-II — — 
Abbreviations: Ind, Indeterminate Western blot; —, samples not analyzed. 
a Samples initially seroreactive on ELISA (Pos) were further analyzed by Western blot and RFLP analysis to differentiate 
HTLV-I and HTLV-II infections (pX) and the HTLV-IIa and HTLV-IIb subtypes (env). 
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TABLE 2. WESTERN BLOT PROFILES OF 
SAMPLES WITH INDETERMINATE SEROLOGY THAT 
WERE POSITIVE FOR HTLV-II INFECTION BY PCR 
Western blot band Patient 
number Gag Env Other 
DUB991 None GD21 None 
DUB611 None GD21, 
rgp46-II 
None 
DUB717 p24 GD21 None 
DUB812 p24 None None 
both HTLV-I and HTLV-II (Table 1), and as such we were 
unable to confirm that this in fact represented dual 
infection. 
Nucleotide sequence and phylogenetic analysis 
 Five samples were chosen randomly for nucleotide 
sequence analysis of the LTR region. An 831-nuclcotide 
product was amplified from the LTR and sequenced, and 
of this. 623 nu-cleotides corresponding to nucleotides 86-
707 of the prototype isolate HTLV-!la Mo-T were used in 
the phylogenctic analysis. Absolute nucleotide sequence 
variation between the five Dublin samples and the HTLV-
IIa Mo-T isolate ranged from 1.7 to 2.1%. The five Dublin 
sequences alone displayed divergence of 0.16 to 0.32%. 
Phylogenetic trees were constructed and evaluated by three 
different methods: neighbor joining (NJ), parsimony (pars), 
and maximum likelihood. NJ and pars trees were 
statistically evaluated using 1000 molecular bootstrap 
replicates. All of the methods resulted in trees of similar 
topology with well-documented separation of the HTLV-
IIa and HTLV-IIb subtypes (Fig. 1). The five Dublin 
samples clearly clustered in the HTLV-IIa group by all 
three methods and the bootstrap values for the NJ and pars 
trees clearly supported the inclusion of the Dublin 
sequences in the HTLV-IIa clade. Using the NJ method 
with 1000 bootstraps, the calculated value for the HTLV-
IIa subtypes was 1000/1000 and for the HTLV-IIb subtype 
it was 600/1000. In the pars analysis the HTLV-IIa subtype 
also had a value of 1000/1000 and for the HTLV-IIb 
subtype, it was 941/1000. For the ML method the 
clustering of the HTLV-IIa and -lib subtypes displayed a p; 
value of <0.01. 
 In each of the trees the Dublin samples clustered 
with the other 1VDA strains of the HTLV-IIa subtype, 
including four isolates from the United States: Los Angeles 
(LASA). Atlanta (ATL18), and San Francisco (SFIDU a0 
5-5, SF1DU a2 6-2J44; three isolates from Europe, which 
included two from the United Kingdom (SMH1 SMH2)45 
and one from Norway (NOR2N); and with a Pueblo Indian 
isolate (PUEB.RB) (Fig. 1). Using the NJ method the 
bootstrap value for this group was 816/1000, and using the 
pars analysis it was 549/1000. The ML method showed 
that this was highly significant, with a p value of <0.01. 
These values demonstrate that a distinct HTLV-IIa IVDA 
clade was well supported by all three methods. 
DISCUSSION 
 In the present study we have employed serological 
and molecular methods to characterize human T 
lymphotropic virus (HTLV) infections in a cohort of 
intravenous drug abusers (IV- 
DAs) in Dublin. Ireland. All individuals studied were of 
Irish descent and were attending a drug rehabilitation 
and/or a sexually transmitted disease clinic. Initial 
screening of 103 .sera using a commercial ELISA 
demonstrated immunoreactivity in 16 (15.5%): Western 
blotting confirmed infection in 12, with the remaining 4 
having indeterminate patterns. Of the former, 11 (10.7%) 
had patterns consistent with HTLV-II infection and 1 had a 
pattern suggestive of dual HTLV-I and HTLV-II infection. 
PCR with RFLP analysis of the tax region of the provirus 
was used to confirm infection in seven of the HTLV-II-
seropositive samples and to analyze further the four WB 
indeterminate samples. All of the former were confirmed 
as having HTLV-H infection and, in addition, all of the 
indeterminate samples were also shown to be HTLV-II 
infected by this method. The latter observation supports 
previous reports that certain individuals with HTLV-II 
infection can be sero-indeterminate or even seronegalive.20 
As noted, one individual appeared to be coinfected with 
HTLV-I and HTLV-II: however, venous blood samples 
were not available and PCR analysis could not be used to 
confirm this. Of the 15 individuals with single HTLV-I1 
infection (11 Western blot positive and 4 Western blot 
indeterminate), 4 were female (12.5%) and 11 were male 
(15.5%), and the average age was 36.1 years. 
Unfortunately, because of unreliable and inconsistent 
histories we were unable to ascertain if there was a 
correlation between HTLV-II infection and total years of 
intravenous drug abuse. 
To identify the HTLV-II molecular subtypes and to 
characterize further the viruses, additional RFLP and 
nucleotide sequence analyses were employed. RFLP 
analysis of the env gene region demonstrated that all 
samples were infected with the HTLV-IIa subtype. This 
finding contrasts with a number of studies from southern 
Europe and specifically in regions of Italy28-30,32 and 
Spain,33-37 where the HTLV-IIb subtype predominates and 
in some instances is the exclusive infection. A single report 
has suggested that, similar to Ireland, the HTLV-IIa 
subtype appears to predominate in an IVDA population in 
Stockholm, Sweden.39 In comparison with other studies, 
where prevalence rates have been reported to range 
between 0 and 6.5%, the Irish infection rate is the highest 
yet reported for any European country,18,20,28-39,46-48 and on 
the basis of PCR analysis this was 14.6%. of the cohort 
studied. It should be noted that all of the Irish patients 
tested were coinfectcd with human immunodeficiency type 
1 virus (HIV-1). In other studies it has also been found that 
the prevalence of HTLV infection, and particularly HTLV-
II, is much higher in HIV-positive populations. In one 
Swedish study it was found that of 1158 IVDAs tested for 
HTLV-I/II, 2.4% were seropositive, whereas if only the 
HIV-infected IVDA patients in this cohort were examined 
the prevalence rose to 11.4%.47 In a Spanish HTLV-II-
positive cohort of IVDAs it was found that 84% of their 
patients were coinfected with HIV-1.35 It is unclear if the 
high rate of infection observed in this Irish cohort is 
representative of all IVDAs, and not just those who are 
HIV-1 infected. Unfortunately, we have up to now been 
unable to recruit significant numbers of non-HIV-1-in-
fected IVDAs in our studies. However, we are currently 
attempting to establish such a cohort to determine if the 
rates of infection differ between the two populations. The 
finding of the two subtypes of HTLV-I1 in geographically 
different parts of Europe would indicate that infection 
probably has been introduced to Europe at different times. 
It is unclear if the introduction 
 
FIG. 1. Phylogenetic analysis of the LTR sequences (corresponding to nucleotides 86-707 of the prototype HTLV-IIa Mo-
T isolate) constructed using the neighbor-joining method. Included in the analysis were HTLV-IIa strains from the five 
Irish IVDA strains (DUB095. DUB500, DUB408. DUB496, and DUB991), in bold face print, IVDAs from the United 
Stales and Europe (ATLI8, LAS, SF a0 5-5, SF a2 6-2, Norn2, SMH I, and SMH 2). Brazilian Indians (SPWV; Braz.A21, 
KAY73, and KAY139), North American Indians (PUEB.RR and NAV.DS), and a Mexican child prostitute (Mexy 17). 
HTLV-IIb sequences came from American and European IVDAs (Nra. JG, NY 185, PENN7A, Gu, JTA47A, 1TA50A, 
SPANI29, SPAN130, I-AM, I-EC, I-IT, I-EA, I-GI, I-OG, I-OV, RC, BF, DP, AA, JA, JL, JAN, 130, 324, RVP, SF bx 4-
10, and SF bx 6-4), North American Indians (PUEB-AG, SEM1050, and SEM1051). Colombian Indians (G12, WYUI, 
and WYU2) and a Cameroon pygmy (PYGCAM I). An HTLV-IId LTR sequence from an Efc pygmy from the 
Democratic Republic of Congo/Zaire (Efe2) was also included in the analysis. The tree was rooted with a primate T cell 
lymphotropic virus (PTLV) LTR sequence (PP1664) isolated from a pygmy chimpanzee, Pan paniscus. Details of the 
different strains used are given in Malenals and Methods. Statistical evaluation was done with 1000 bootstrap replicates 
whose values are shown on the branches. Horizontal branch lengths are drawn to scale; the bar represents 1% divergence. 
The tree clearly shows the clustering of the HTLV-IIa and -lib subtypes, with the five Irish IVDA strains grouped in the 
IIa clade with the HTLV-IIa American and European IVDAs, a Pueblo Indian, and the Mo-T isolate (Mo). 
of HTLV-IIa infection to Ireland may have occurred 
recently, as has been suggested in a Swedish study.47 
However, screening of a limited number of archival 
serological samples from IVDAs in Dublin, which were 
obtained more than a decade ago, have suggested that few 
of these were infected with HTLV- 
II (our unpublished data, 1998) and would support the view 
that infection has also been recently introduced. 
 A total of 623 nucleotides of the LTR region from 
five of the Dublin samples and all other available HTLV-II 
isolates was used to construct phylogenctic trees using 
neighbor joining (NJ), 
Fitch and Wagner parsimony (pars), and maximum 
likelihood (ML) methods. The grouping of the Dublin 
simples in the HTLV-IIa clade could be clearly 
demonstrated by each method. The bootstrap values for the 
clade from the NJ and pars analyses (1000/1000 for each) 
supported this classification, as did the probability values 
in the ML method (p value < 0.01). The phy-logenetic 
analysis also demonstrated the close relationship of (he 
HTLV-IIa in the Dublin IVDAs with that found in four 
IVDAs from the United States (Atlanta, Los Angeles, and 
San Francisco) and three from Europe (two from the 
United Kingdom and one from Norway). Unfortunately, 
nucleotide sequence data from the Swedish HTLV-II 
isolates are not available and the relationship of these 
isolates to those in Ireland cannot be determined. It has 
been reported that infection with the HTLV-IIa subtype is 
the predominant infection among IVDAs in the United 
Slates, and it could be speculated that this might be the 
origin of infection in Dublin. Further studies are now 
necessary to determine if there has been any transmission 
of the virus to IVDAs in other parts of Ireland and to other 
high-risk groups. At present the role of HTLV-II in human 
disease is poorly understood. Evaluation of the clinical 
features in our population, which has such a high rate of 
infection, may allow a better understanding of this and of 
possible clinical sequelae resulting from interactions of 
concomitant HIV-1 and HTLV-II infections. 
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